ANCA vasculitis: time for a change in treatment paradigm? Not yet. (25/99)

 (+info)

Valvular involvement in ANCA-associated systemic vasculitis: a case report and literature review. (26/99)

 (+info)

In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations. (27/99)

 (+info)

Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. (28/99)

 (+info)

Kaposi's sarcoma following immunosuppressive therapy for vasculitis. (29/99)

Kaposi's sarcoma (KS) is widely reported to develop after renal transplantation and is induced by activation of a latent human herpes virus 8. We report the clinical features and outcome of a 50-year-old woman who presented with KS 18 weeks after starting immunosuppressive therapy for vasculitis. She had positive-titer IgG antibody to human herpes virus 8. Cyclophosphamide pulses were interrupted, and prednisone was decreased gradually to 10 mg/day. Skin lesions showed important regression with stabilization of the general state and renal function. Eight months later, the patient presented with a diffuse cutaneous KS that required the discontinuation of steroids. Within 1 month, her general status and renal function deteriorated, and she died with a disseminated intravascular coagulation syndrome.  (+info)

Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis. (30/99)

 (+info)

Epigenetics and complementary proteins. (31/99)

 (+info)

Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. (32/99)

 (+info)